10-K · February 26, 2026
Aclaris is a clinical-stage immuno-inflammatory biopharma emphasizing biologics (TSLP and bispecific TSLP/IL-4Rα) and small-molecule ITK programs driven by its KINect discovery platform. The 10-K highlights multiple…
Earnings analysis · 10-Q
ACRS earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Aclaris Therapeutics reported strong Q1 2026 earnings with revenues of $1.996 million, exceeding estimates significantly. Although the company continued to incur losses, reporting a net loss of $19.8 million, it…
Read full summary
Aclaris Therapeutics reported strong Q1 2026 earnings with revenues of $1.996 million, exceeding estimates significantly. Although the company continued to incur losses, reporting a net loss of $19.8 million, it maintained a solid cash position of $190.8 million, indicating stability in funding future operations.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.15
What stood out
-
Revenue Growth Exceeds Estimates
Actual revenue for Q1 2026 was $1.996 million, a 37.2% increase from $1.455 million in Q1 2025, surpassing estimates by 49.9%.
-
Improved EPS Performance
Reported EPS was -$0.15, compared to -$0.12 in Q1 2025, a smaller loss indicating improved relative performance.
-
Strong Cash Position
As of March 31, 2026, Aclaris had cash, cash equivalents, and marketable securities totaling $190.8 million, up from $131.4 million at year-end 2025.
-
Increased Licensing Revenue
Licensing revenue increased to $1.459 million in Q1 2026 from $1.010 million in Q1 2025, due to higher royalties under license agreements.
-
Positive Developments in Clinical Trials
Management highlighted encouraging preliminary results from ongoing clinical trials, particularly for bosakitug and ATI-052.
-
Capital Raising Success
In March 2026, Aclaris raised $59.8 million from the sale of common stock, enhancing its liquidity.
What to watch
-
High Net Losses
Net loss reported for Q1 2026 was $19.8 million, significantly higher than the $15.1 million loss in Q1 2025.
-
Operational Cash Flow Concerns
Cash used in operating activities increased to $18.149 million in Q1 2026 from $13.057 million in Q1 2025.
-
Dependence on Future Clinical Success
Continued reliance on successful outcomes from clinical trials and regulatory approvals poses a substantial risk to cash flow.
Management's outlook
Aclaris expects to continue funding operations through 2028 based on current liquidity.
Earlier filings 4
10-Q · August 7, 2025
Aclaris reported quarterly revenue of $1.777M for Q2 2025, down from $2.766M in Q2 2024, while GAAP net loss widened to $15.429M (−$0.13/share) despite EPS improving vs prior-year quarter due to a larger share base.…
10-Q · November 6, 2024
Aclaris reported Q3 revenue of $4,346,000, down from $9,282,000 in Q3 2023, driven by a sharp decline in licensing revenue. Gross margin remained high at ~85% (revenue $4,346,000 less cost of revenue $654,000) and…
10-Q · August 7, 2023
Aclaris reported Q2 2023 revenue of $1,869,000 (up from $1,528,000 in Q2 2022) and a GAAP net loss per share of $(0.42). Licensing revenue drove the top-line increase while R&D spend rose materially, pushing loss from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.